<p>Eli Lilly and Co said late on Tuesday it had hired an independent consultant to review a plant producing its promising COVID-19 drug after receiving notices from the US health regulator.</p>.<p>The company reiterated that it had not received a warning letter from the US Food and Drugs Administration following inspections at the plant first revealed by Reuters last week.</p>.<p>The company, however, also reiterated that it had received an Official Action Indicated (OAI) notice from the FDA in relation to issues at its Branchburg plant in New Jersey</p>
<p>Eli Lilly and Co said late on Tuesday it had hired an independent consultant to review a plant producing its promising COVID-19 drug after receiving notices from the US health regulator.</p>.<p>The company reiterated that it had not received a warning letter from the US Food and Drugs Administration following inspections at the plant first revealed by Reuters last week.</p>.<p>The company, however, also reiterated that it had received an Official Action Indicated (OAI) notice from the FDA in relation to issues at its Branchburg plant in New Jersey</p>